Eris Lifesciences Limited Q1FY22 Revenues at INR 3,493 mn, up 19.1% YoY

Eris Lifesciences Limited Q1FY22 Revenues at INR 3,493 mn, up 19.1% YoY

Consolidated Financial Highlights:

Particulars

(INR million)

Q1FY22 Q1FY21 YoY(%)
Revenue 3,493 2,932 19.1%
Gross Profit 2,804 2,357 19.0%
EBITDA 1,265 1,041 21.6%
EBITDA Margin 36.2% 35.5% 74bps
PAT 1,067 890 19.8%
PAT Margin 30.5% 30.4% 18bps

Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., said, “After significantly outperforming our covered market in FY 21 for the third consecutive year, we witnessed significant outperformance in our Top 3 core therapies in Q1 FY22 on the strength of our predominantly chronic and sub-chronic portfolios. We believe that our focus on building strong brands in fast growing therapies coupled with several patent expiration opportunities will enable us to sustain this growth trajectory.”

Mr. Krishnakumar V, Executive Director & Chief Operating Officer of Eris Lifesciences Ltd., added, “Our focus on building a strong franchise of power brands in cardio-metabolic and VMN continues to drive our growth. Ten out of our Top-15 mother brands are ranked among the Top-5 within their respective segments. We successfully launched 3 new products this quarter – Zomelis SG, Remylin DX and Zac Day. Our latest-generation Diabetes products Zomelis and Gluxit continue to enjoy #1 market ranks and robust growth. We have an exciting period of organic growth coming in the next 4 – 5 years, driven by multiple factors like consolidation of power brands franchise, new launch pipeline, expansion of physician coverage and therapeutic diversification. We continue to look for high-return in-licensing and acquisition opportunities, in order to supplement our organic growth initiatives.”

News Links

Copyright © 2022 Eris Lifesciences Limited. All Rights Reserved.